PT  - JOURNAL ARTICLE
AU  - Thao T. Truong
AU  - Alex Ryutov
AU  - Utsav Pandey
AU  - Rebecca Yee
AU  - Lior Goldberg
AU  - Deepa Bhojwani
AU  - Paibel Aguayo-Hiraldo
AU  - Benjamin A. Pinsky
AU  - Andrew Pekosz
AU  - Lishuang Shen
AU  - Scott D. Boyd
AU  - Oliver F. Wirz
AU  - Katharina Röltgen
AU  - Moiz Bootwalla
AU  - Dennis T. Maglinte
AU  - Dejerianne Ostrow
AU  - David Ruble
AU  - Jennifer H. Han
AU  - Jaclyn A. Biegel
AU  - Maggie Li ScM
AU  - ChunHong Huang
AU  - Mayala K. Sahoo
AU  - Pia S. Pannaraj
AU  - Maurice O’Gorman
AU  - Alexander R. Judkins
AU  - Xiaowu Gai
AU  - Jennifer Dien Bard
TI  - Persistent SARS-CoV-2 infection and increasing viral variants in children and young adults with impaired humoral immunity
AID  - 10.1101/2021.02.27.21252099
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.02.27.21252099
4099  - http://medrxiv.org/content/early/2021/03/02/2021.02.27.21252099.short
4100  - http://medrxiv.org/content/early/2021/03/02/2021.02.27.21252099.full
AB  - Background There is increasing concern that persistent infection of SARS-CoV-2 within immunocompromised hosts could serve as a reservoir for mutation accumulation and subsequent emergence of novel strains with the potential to evade immune responses.Methods We describe three patients with acute lymphoblastic leukemia who were persistently positive for SARS-CoV-2 by real-time polymerase chain reaction. Viral viability from longitudinally-collected specimens was assessed. Whole-genome sequencing and serological studies were performed to measure viral evolution and evidence of immune escape.Findings We found compelling evidence of ongoing replication and infectivity for up to 162 days from initial positive by subgenomic RNA, single-stranded RNA, and viral culture analysis. Our results reveal a broad spectrum of infectivity, host immune responses, and accumulation of mutations, some with the potential for immune escape.Interpretation Our results highlight the need to reassess infection control precautions in the management and care of immunocompromised patients. Routine surveillance of mutations and evaluation of their potential impact on viral transmission and immune escape should be considered.Funding The work was partially funded by The Saban Research Institute at Children’s Hospital Los Angeles intramural support for COVID-19 Directed Research (X.G. and J.D.B.), the Johns Hopkins Center of Excellence in Influenza Research and Surveillance HHSN272201400007C (A.P.), NIH/NIAID R01AI127877 (S.D.B.), NIH/NIAID R01AI130398 (S.D.B.), NIH 1U54CA260517 (S.D.B.), an endowment to S.D.B. from the Crown Family Foundation, an Early Postdoc.Mobility Fellowship Stipend to O.F.W. from the Swiss National Science Foundation (SNSF), and a Coulter COVID-19 Rapid Response Award to S.D.B. L.G. is a SHARE Research Fellow in Pediatric Hematology-Oncology.Competing Interest StatementS.D.B. has consulted for Regeneron, Sanofi, and Novartis on topics unrelated to this study. S.D.B., and K.R. have filed provisional patent applications related to serological tests for SARS-CoV-2 antibodies. All other authors have no competing interests.Funding StatementThe work was partially funded by The Saban Research Institute at Childrens Hospital Los Angeles intramural support for COVID-19 Directed Research (X.G. and J.D.B.), the Johns Hopkins Center of Excellence in Influenza Research and Surveillance HHSN272201400007C (A.P.), NIH/NIAID R01AI127877 (S.D.B.), NIH/NIAID R01AI130398 (S.D.B.), NIH 1U54CA260517 (S.D.B.), an endowment to S.D.B. from the Crown Family Foundation, an Early Postdoc.Mobility Fellowship Stipend to O.F.W. from the Swiss National Science Foundation (SNSF), and a Coulter COVID-19 Rapid Response Award to S.D.B. L.G. is a SHARE Research Fellow in Pediatric Hematology-Oncology.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the CHLA Institutional Review Board (CHLA-16-00429).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe manuscript contains all relevant data.